Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease

Autor: Jaime Adams, Samuel Frank, Deborah Baker, Saurav Brahmachari, Elizabeth A. Klingner, Jason Aldred, Jennifer Mule, Meredith Spindler, Cornelia Kamp, Phounsavath Muneath, Claudia Rocha, Liana Baker, Gian Pal, Doozie Russell, Yvette Pitchford, Tina Ward, Olga Kishchenko, Kellie Keith, Angela S Stovall, Courtney Blair, John Slevin Slevin, Vanessa K. Hinson, Grace Bwala, Brian K. Fiske, Liana S. Rosenthal, Joohi Shahed, Andrew P. Duker, Patrick Bolger, Gary Rafaloff, David Weiner, Adolfo Ramirez-Zamora, Zoltan Mari, Renee Wagner Wagner, Helen Matthews, Karen Blindauer, Derek B. Ridgeway, Alexandria Oliver, Carlinda Field, Stephanie Burrows, Binit B. Shah, Lauren Seeberger, Charles S. Venuto, Katie Sullivan, Laura Ramirez, Erika F. Augustine, Matthew Swan, Lilliana Dumitrescu, Natividad Stover, Shonna Jenkins, Sharon Evans, Lin Zhang, Anwar Ahmed, Tanya Simuni, Michael A. Schwarzschild, Christopher S. Coffey, Mark S. LeDoux, David-Erick Lafontant, Laura Trusso, Farah Ismail, John L. Goudreau, Eric Molho, Sue Henderson, Cindy Casaceli, Christine Hunter, Holly Reynolds, Albert Y. Hung, Robert A. Hauser, Burton L. Scott, Lynn Wheeler, Kalpana Merchant, Chelsea Caspell-Garcia, Claire E. Wegel, Richard K. Wyse, Patrik Brundin, Christina Gruenwald, Alicia Brocht, Candace Cromer, Lisa Gauger, Melissa Bixby, Emily Carman, Kathryn A. Chung, Nichole McMullen, David Simon, Ken Eaton, Oren A. Levy, Amber Servi, Abigail Simpson, Holly A. Shill, Kelvin L. Chou, Melissa Kostrzebski, Ted M. Dawson

Publikováno v: JAMA Neurology. 78:312

Importance There is a critical need for careful and independent validation of reported symptomatic efficacy and dopaminergic biomarker changes induced by nilotinib in Parkinson disease (PD). Objectives To assess safety and tolerability of nilotinib i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8da5bef13be163263b4f128491abd097
https://doi.org/10.1001/jamaneurol.2020.4725